Apr 18 |
Ocular Therapeutix Highlights Early Data From Diabetes-Related Eye Disorder
|
Apr 18 |
Ocular marks early-stage trial win for diabetic retinopathy candidate
|
Apr 18 |
Ocular Therapeutix™ Announces Positive Topline Phase 1 Data for AXPAXLI™ in Diabetic Retinopathy
|
Apr 16 |
The 3 Best Biotech Stocks to Buy Now: Q2 Edition
|
Apr 16 |
Ocular Therapeutix™ Strengthens Clinical Team with Appointment of Key Retinal Leaders
|
Apr 15 |
Ocular Therapeutix names its chair Dugel as new CEO
|
Apr 15 |
Ocular Therapeutix™ Executive Chairman Pravin U. Dugel, MD Becomes President and CEO Antony Mattessich is Stepping Down as President and CEO
|
Apr 9 |
Down -17.88% in 4 Weeks, Here's Why Ocular Therapeutix (OCUL) Looks Ripe for a Turnaround
|
Apr 9 |
Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Senior Vice President of Global Head of Biometrics
|
Apr 6 |
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
|